دورية أكاديمية
أعرض في EDS

Effects of Low Doses of L-Carnitine Tartrate and Lipid Multi-Particulate Formulated Creatine Monohydrate on Muscle Protein Synthesis in Myoblasts and Bioavailability in Humans and Rodents.

التفاصيل البيبلوغرافية
العنوان: Effects of Low Doses of L-Carnitine Tartrate and Lipid Multi-Particulate Formulated Creatine Monohydrate on Muscle Protein Synthesis in Myoblasts and Bioavailability in Humans and Rodents.
المؤلفون: Fielding RA; Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Aging Tufts University, Boston, MA 02111, USA., Rivas D; Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Aging Tufts University, Boston, MA 02111, USA., Grosicki GJ; Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Aging Tufts University, Boston, MA 02111, USA.; Biodynamics and Human Performance Center, Georgia Southern University, Armsrong Campus, Savannah, GA 31419, USA., Ezzyat Y; Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Aging Tufts University, Boston, MA 02111, USA., Ceglia L; Division of Endocrinology, Tufts Medical Center, Boston, MA 02111, USA., Price LL; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA.; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA 02111, USA., Orhan C; Department of Animal Nutrition, Faculty of Veterinary Medicine, Firat University, Elazig 23119, Turkey., Sahin K; Department of Animal Nutrition, Faculty of Veterinary Medicine, Firat University, Elazig 23119, Turkey., Fowler K; R&D Innovation, Lonza Consumer Health, Morristown, NJ 07960, USA., White T; R&D Innovation, Lonza Consumer Health, Morristown, NJ 07960, USA., Durkee S; R&D Innovation, Lonza Consumer Health, Morristown, NJ 07960, USA., Kritsch K; R&D Lonza Specialty Ingredients, Alpharetta, GA 30004, USA., Bellamine A; R&D Innovation, Lonza Consumer Health, Morristown, NJ 07960, USA.
المصدر: Nutrients [Nutrients] 2021 Nov 09; Vol. 13 (11). Date of Electronic Publication: 2021 Nov 09.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI Publishing
مواضيع طبية MeSH: Carnitine/*pharmacology , Creatine/*pharmacology , Lipids/*chemistry , Muscle Proteins/*biosynthesis , Myoblasts/*metabolism , Protein Biosynthesis/*drug effects, Adolescent ; Adult ; Animals ; Biological Availability ; Cells, Cultured ; Creatine/pharmacokinetics ; Female ; Humans ; Male ; Myoblasts/drug effects ; Phosphorylation/drug effects ; Proto-Oncogene Proteins c-akt/metabolism ; Rats, Wistar ; Ribosomal Protein S6/metabolism ; Signal Transduction/drug effects ; Young Adult ; Rats
مستخلص: The primary objective of this study was to investigate the potential synergy between low doses of L-carnitine tartrate and creatine monohydrate to induce muscle protein synthesis and anabolic pathway activation in primary human myoblasts. In addition, the effects of Lipid multi-particulates (LMP) formulation on creatine stability and bioavailability were assessed in rodents and healthy human subjects. When used individually, L-carnitine tartrate at 50 µM and creatine monohydrate at 0.5 µM did not affect myoblast protein synthesis and signaling. However, when combined, they led to a significant increase in protein synthesis. Increased AKT and RPS6 phosphorylation were observed with 50 µM L-carnitine tartrate 5 µM creatine in combination in primary human myoblasts. When Wistar rats were administered creatine with LMP formulation at either 21 or 51 mg/kg, bioavailability was increased by 27% based on the increase in the area under the curve (AUC) at a 51 mg/kg dose compared to without LMP formulation. Tmax and Cmax were unchanged. Finally, in human subjects, a combination of LMP formulated L-carnitine at 500 mg (from L-carnitine tartrate) with LMP formulated creatine at 100, 200, or 500 mg revealed a significant and dose-dependent increase in plasma creatine concentrations. Serum total L-carnitine levels rose in a similar manner in the three combinations. These results suggest that a combination of low doses of L-carnitine tartrate and creatine monohydrate may lead to a significant and synergistic enhancement of muscle protein synthesis and activation of anabolic signaling. In addition, the LMP formulation of creatine improved its bioavailability. L-carnitine at 500 mg and LMP-formulated creatine at 200 or 500 mg may be useful for future clinical trials to evaluate the effects on muscle protein synthesis.
References: Exerc Sport Sci Rev. 2013 Apr;41(2):107-15. (PMID: 23089927)
J Am Med Dir Assoc. 2011 May;12(4):249-56. (PMID: 21527165)
Expert Rev Proteomics. 2020 Nov-Dec;17(11-12):813-825. (PMID: 33470862)
Nutr Metab (Lond). 2017 Jan 18;14:7. (PMID: 28115977)
Subcell Biochem. 2007;46:261-73. (PMID: 18652081)
Curr Protoc Hum Genet. 2017 Apr 6;93:A.3O.1-A.3O.7. (PMID: 28384398)
Nutr Rev. 2006 Feb;64(2 Pt 1):80-8. (PMID: 16536185)
Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E474-82. (PMID: 11788381)
Nutrients. 2018 Mar 13;10(3):. (PMID: 29534031)
J Chromatogr Sci. 2011;49(6):463-8. (PMID: 21682996)
Calcif Tissue Int. 2015 Mar;96(3):256-63. (PMID: 25479835)
Nutrients. 2016 Mar 29;8(4):186. (PMID: 27043616)
Clin Chem. 2004 Jan;50(1):201-3. (PMID: 14709648)
PLoS Negl Trop Dis. 2020 Aug 20;14(8):e0008282. (PMID: 32817655)
Acta Physiol Scand. 2002 Jan;174(1):57-65. (PMID: 11851597)
Ageing Res Rev. 2015 Nov;24(Pt B):304-27. (PMID: 26462882)
Amino Acids. 2011 May;40(5):1369-83. (PMID: 21424716)
Biomed Res Int. 2019 Feb 17;2019:2042808. (PMID: 30906768)
Clin Sci (Lond). 1993 May;84(5):565-71. (PMID: 8504634)
Ann Clin Transl Neurol. 2016 Jun 23;3(7):537-46. (PMID: 27386502)
FEBS Lett. 2004 Jan 16;557(1-3):243-7. (PMID: 14741375)
Int J Sport Nutr. 1995 Jun;5 Suppl:S100-10. (PMID: 7550252)
Physiol Rev. 2000 Jul;80(3):1107-213. (PMID: 10893433)
معلومات مُعتمدة: UL1 TR002544 United States TR NCATS NIH HHS; P30AG031679 United States AG NIA NIH HHS
فهرسة مساهمة: Keywords: carnitine; creatine; muscle; protein synthesis
المشرفين على المادة: 0 (Lipids)
0 (Muscle Proteins)
0 (Ribosomal Protein S6)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
MU72812GK0 (Creatine)
S7UI8SM58A (Carnitine)
تواريخ الأحداث: Date Created: 20211127 Date Completed: 20211209 Latest Revision: 20240226
رمز التحديث: 20240226
مُعرف محوري في PubMed: PMC8625796
DOI: 10.3390/nu13113985
PMID: 34836240
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6643
DOI:10.3390/nu13113985